INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Scope & Guideline

Championing Excellence in Psychopharmacological Research

Introduction

Immerse yourself in the scholarly insights of INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0268-1315
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1986 to 2024
AbbreviationINT CLIN PSYCHOPHARM / Int. Clin. Psychopharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal 'INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY' primarily focuses on the advancements and challenges in psychopharmacology, emphasizing clinical implications and the treatment of various psychiatric disorders through pharmacological interventions. It serves as a platform for research that bridges the gap between laboratory findings and clinical practice.
  1. Clinical Efficacy and Safety of Psychopharmacological Interventions:
    The journal publishes studies that assess the efficacy and safety profiles of various psychopharmacological agents, including novel medications for mood disorders, schizophrenia, and treatment-resistant cases.
  2. Pharmacogenetics and Personalized Medicine:
    Research on pharmacogenetic analyses and therapeutic drug monitoring is a core focus, aiming to tailor antidepressant and antipsychotic treatments based on individual patient profiles.
  3. Psychiatric Comorbidities and Somatic Conditions:
    Papers often explore the interplay between psychiatric disorders and somatic health issues, such as metabolic syndrome and diabetes, which are crucial for comprehensive patient care.
  4. Innovative Treatment Strategies:
    The journal highlights innovative treatment approaches, including the use of long-acting injectable antipsychotics and adjunctive therapies, to improve adherence and outcomes in patients with severe mental illnesses.
  5. Case Reports and Observational Studies:
    The inclusion of case reports and observational studies provides insights into real-world applications of psychopharmacological treatments, contributing to evidence-based practice.
The recent publications in 'INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY' indicate a shift towards emerging themes that reflect current challenges and innovations in the field of psychopharmacology.
  1. Treatment-Resistant Depression:
    There is an increasing focus on innovative treatments for treatment-resistant depression, including the use of ketamine and esketamine, highlighting a shift towards exploring alternative therapies.
  2. Impact of Medical Comorbidities on Psychiatric Treatment:
    Recent studies are emphasizing the effects of medical comorbidities, such as diabetes and cardiovascular conditions, on psychiatric treatment outcomes, indicating a more integrated approach to patient management.
  3. Pharmacogenetic Approaches for Personalized Treatment:
    The trend towards personalized medicine in psychiatry is reflected in the growing number of studies focusing on pharmacogenetics and tailored treatment strategies based on genetic profiles.
  4. Long-Acting Injectable Antipsychotics:
    Research on long-acting injectable antipsychotics has gained momentum, particularly regarding their impact on treatment adherence and patient outcomes in severe mental illness.
  5. Neuroinflammation and Psychiatric Disorders:
    Emerging themes include the role of neuroinflammation in psychiatric disorders, exploring how inflammatory processes may contribute to the pathophysiology of conditions like depression and schizophrenia.

Declining or Waning

While the journal has consistently focused on several key areas of psychopharmacology, some themes appear to be declining in prominence based on recent publications.
  1. Traditional Antidepressant Therapies:
    Research on older classes of antidepressants, such as tricyclics and older SSRIs, seems to be waning as newer agents and innovative treatments gain more attention.
  2. Longitudinal Studies on Established Medications:
    There is a noticeable decrease in longitudinal studies examining the long-term effects of established medications, potentially overshadowed by newer treatment modalities and their rapid evaluation.
  3. Generalized Anxiety Disorders:
    Publications focusing specifically on generalized anxiety disorders and their pharmacological treatment have diminished, suggesting a shift towards more complex and treatment-resistant cases.
  4. Neuroleptic Malignant Syndrome Reports:
    Case reports and studies specifically addressing neuroleptic malignant syndrome and similar acute reactions have become less frequent, possibly due to improved awareness and management strategies.
  5. Focus on Non-Pharmacological Interventions:
    While there is some interest in the intersection of psychopharmacology and psychotherapy, the specific focus on non-pharmacological interventions appears to be less prominent in recent issues.

Similar Journals

Journal of the Academy of Consultation-Liaison Psychiatry

Transforming Mental Health Understanding and Practice.
Publisher: ELSEVIER SCIENCE INCISSN: 2667-2960Frequency: 6 issues/year

The Journal of the Academy of Consultation-Liaison Psychiatry, published by Elsevier Science Inc, stands as a pivotal resource in the fields of clinical psychology and psychiatry, with a commendable impact factor that reflects its significance in mental health research. Established in 2021, this journal has rapidly ascended within its domain, achieving a Q2 category ranking in both Clinical Psychology and Psychiatry and Mental Health as of 2023, placing it among the top journals in these fields. With a Scopus ranking of 64 out of 311 in clinical psychology and 163 out of 567 in psychiatry, it serves as an essential platform for researchers, professionals, and students to access high-quality articles that advance knowledge and practices in consultation-liaison psychiatry. The journal promotes open access initiatives, enhancing the reach and impact of its publications, and is committed to disseminating innovative research findings that contribute to improving patient care and understanding of mental health complexities. Whether you are engaged in academic, clinical, or applied research, the Journal of the Academy of Consultation-Liaison Psychiatry is your go-to source for evidence-based insights and groundbreaking studies.

Current Psychiatry Reports

Pioneering discussions in contemporary psychiatry.
Publisher: SPRINGERISSN: 1523-3812Frequency: 12 issues/year

Current Psychiatry Reports, published by Springer, is a premier academic journal dedicated to the dissemination of cutting-edge research in the field of psychiatry and mental health. With a significant impact factor reflecting its esteemed position at Q1 in Psychiatry, this journal ranks an impressive #35 out of 567 in its category, placing it within the 93rd percentile of psychiatric publications as per Scopus metrics. Since its inception in 1996, it has provided a vital platform for clinicians, researchers, and students to explore and discuss contemporary psychiatric issues, advancements, and methodologies. While Current Psychiatry Reports is a subscription-based journal, its robust scholarly contributions are invaluable for practitioners and scholars looking to stay abreast of developments and empirical studies that shape the field. Based in the United States, at ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY 10004, it remains an authoritative source for evidence-based insights that guide both research and clinical practice in mental health.

BIPOLAR DISORDERS

Exploring Innovative Treatments and Insights
Publisher: WILEYISSN: 1398-5647Frequency: 8 issues/year

BIPOLAR DISORDERS, published by Wiley, is a leading international journal dedicated to advancing the understanding and treatment of bipolar disorders. Since its establishment in 1999, the journal has become a vital resource in the fields of Biological Psychiatry and Psychiatry and Mental Health, currently ranked in the Q2 category for Biological Psychiatry and Q1 for Psychiatry and Mental Health as of 2023. With impressive Scopus rankings, it stands at 75th out of 567 in Psychiatry and Mental Health and 11th out of 51 in Biological Psychiatry, reflecting its influential role in shaping mental health research. The journal not only focuses on empirical studies, reviews, and clinical reports but also encourages innovative methodological advancements in understanding bipolar disorders. Although it does not offer Open Access, its extensive coverage from 1999 to 2024 ensures that practitioners, researchers, and students have access to a wealth of knowledge critical for the development of effective therapeutic interventions. For those engaging with cutting-edge research in psychiatric care, BIPOLAR DISORDERS serves as an essential platform for knowledge dissemination and academic discourse.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Advancing Mental Health Through Innovative Pharmacological Research
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0271-0749Frequency: 6 issues/year

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

JOURNAL OF CLINICAL PSYCHIATRY

Connecting researchers and clinicians to enhance mental health outcomes.
Publisher: PHYSICIANS POSTGRADUATE PRESSISSN: 0160-6689Frequency: 6 issues/year

The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

Therapeutic Advances in Psychopharmacology

Fostering Collaboration for a Healthier Mind
Publisher: SAGE PUBLICATIONS LTDISSN: 2045-1253Frequency: 1 issue/year

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

Obesity Research & Clinical Practice

Innovating Solutions for Global Obesity Challenges
Publisher: ELSEVIER SCI LTDISSN: 1871-403XFrequency: 6 issues/year

Obesity Research & Clinical Practice is an esteemed journal published by ELSEVIER SCI LTD, focusing on cutting-edge research and clinical practices related to obesity and its multifaceted impact on health and wellness. With an ISSN of 1871-403X and an E-ISSN of 1878-0318, this journal serves as a vital resource for researchers and practitioners in the fields of Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics. Notably, it holds a Q2 ranking in Endocrinology, Diabetes and Metabolism and a prestigious Q1 ranking in Nutrition and Dietetics for 2023, reflecting its influence and quality within the scientific community. The journal features a broad scope of research topics encompassing clinical findings, epidemiological studies, and therapeutic advancements in obesity treatment, aiming to improve health outcomes globally. Submissions are encouraged from diverse disciplines, ensuring a dynamic and multidisciplinary approach to tackling obesity-related challenges. Given its convergence of years from 2007 to 2024, Obesity Research & Clinical Practice stands as a prominent platform for disseminating valuable knowledge, insights, and groundbreaking research in this pressing area of public health.

PSYCHIATRIC QUARTERLY

Connecting Theory and Practice in Psychiatric Research
Publisher: SPRINGERISSN: 0033-2720Frequency: 4 issues/year

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Driving innovation in psychopharmacology for healthier futures.
Publisher: MARY ANN LIEBERT, INCISSN: 1044-5463Frequency: 10 issues/year

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.

PSYCHIATRY AND CLINICAL NEUROSCIENCES

Illuminating the Pathways of Mental Health Research
Publisher: WILEYISSN: 1323-1316Frequency: 12 issues/year

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.